Market Place
Sourcing Support
CALQUENCE® Gets US Priority Review For Mantle Cell Lymphoma
03 Oct 2024 //
BUSINESSWIRE
AstraZeneca trumpets new Calquence combos in chronic lymphocytic leukaemia
30 Jul 2024 //
PRESS RELEASE
CALQUENCE Plus Chemoimmunotherapy Reduced MCL Progression Risk
16 Jun 2024 //
BUSINESSWIRE
AstraZeneca aims for $80 bln in total revenue by 2030
21 May 2024 //
REUTERS
Blockbuster cancer drug Calquence hits primary endpoint in trial for first-line mantle cell lymphoma
03 May 2024 //
PRESS RELEASE
CALQUENCE Combo Shows PFS Benefit In 1st-Line Mantle Cell Lymphoma
02 May 2024 //
BUSINESSWIRE
FDA Confirms Para IV Patent for Acalabrutinib Maleate (Calquence) Tablets
01 May 2024 //
FDA
AstraZeneca beats revenue, profit estimates on resilient demand
25 Apr 2024 //
REUTERS
BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib
29 Feb 2024 //
BUSINESSWIRE
Ascentage Pharma and AstraZeneca Enter into Clinical Collaboration
15 Oct 2023 //
PR NEWSWIRE
China NMPA approves AstraZeneca’s BTK inhibitor, Calquence
04 Sep 2023 //
PHARMABIZ
AstraZeneca BTK inhibitor tablet approved in EU for leukaemia
23 Feb 2023 //
EUROPEAN PHARMACEUTICAL REVIEW
Alembic`s Generic Acalabrutinib Receives Approval in the U.S.
18 Jan 2023 //
FDA
Chugai Pharma’s Gazyva gets Japanese MHLW approval for an additional indication
24 Dec 2022 //
PHARMABIZ
CALQUENCE tablet formulation approved in the US across current indications
05 Aug 2022 //
BUSINESSWIRE
CALQUENCE Plus Obinutuzumab Demonstrated Sustained Survival Benefit in CLL
04 Jun 2022 //
BUSINESSWIRE
Aprea Therapeutics Announces Removal of FDA Clinical Hold on Eprenetapopt
09 Dec 2021 //
GLOBENEWSWIRE
AstraZeneca promotes oncology exec to CMO
26 Aug 2021 //
ENDPTS
June 2021 decisions news release
07 Jun 2021 //
FIRSTWORLDPHARMA
Calquence demonstrated fewer incidences of atrial fibrillation versus ibrutinib
07 Jun 2021 //
BUSINESSWIRE
NICE backs AstraZeneca’s Calquence for CLL
20 Mar 2021 //
PHARMATIMES
Chemotherapy-free treatment option to be offered to patients with leukaemia
18 Mar 2021 //
NICE
AstraZeneca, with new data, claims its leukemia drug is safer than Imbruvica
27 Jan 2021 //
BIOPHARMADIVE
Calquence met primary efficacy endpoint in head-to-head trial against ibrutinib
25 Jan 2021 //
PRESS RELEASE
AstraZeneca touts Calquence safety win against Imbruvica in CLL
25 Jan 2021 //
FIERCE PHARMA
NICE backs AZ` Calquence for chronic lymphocytic leukaemia (PharmaTimes)
08 Dec 2020 //
PHARMATIMES
Calquence shows long-term efficacy and tolerability in MCL
07 Dec 2020 //
PHARMATIMES
CALQUENCE Data Across Four Trials Reinforces Cardiovascular Safety Profile
07 Dec 2020 //
BUSINESSWIRE
AZ`s Calquence, BeiGene`s Brukinsa turn heads data, putting Imbruvica on notice
07 Dec 2020 //
FIERCE PHARMA
Calquence fails to prevent respiratory failure in COVID-19 patients
13 Nov 2020 //
EUROPEANPHARMACEUTICALREVIEW
AZ’s CALAVI phase II trials for Calquence in patients hospitalised
12 Nov 2020 //
PHARMABIZ
Calquence Gains EU Approval for Treatment of Chronic Lymphocytic Leukemia
11 Nov 2020 //
PHARMTECH
EU OK for AZ’s Calquence in CLL
10 Nov 2020 //
PHARMATIMES
AZ Pharma India will launch Calquence in India on Oct 21; stock trades flat
16 Oct 2020 //
FIRSTWORDPHARMA
ICMR approaches experts panel to approve testing of cancer drug acalabrutinib
14 Oct 2020 //
ECONOMICTIMES
EMA: Thumbs up for 11, down for 2 new medicines
25 Jul 2020 //
RAPS
Study suggests lymphoma drug acalabrutinib might offer a therapeutic approach
14 Jul 2020 //
NEWSWISEL
Calquence showed long-term efficacy and tolerability for chronic leukaemia
11 Jun 2020 //
PRESS RELEASE
AstraZeneca blood cancer drug shows signs of helping COVID-19 patients
08 Jun 2020 //
REUTERS
AZ` Calquence shows promise for COVID-19
07 Jun 2020 //
PHARMATIMES
AZ’s Calquence Showed Improvement In Small Group Hospitalized Covid-19 Patients
06 Jun 2020 //
FORBES
AstraZeneca blood cancer drug shows signs of helping COVID-19 patients
05 Jun 2020 //
REUTERS
UK hospitals to trial five new drugs in search for coronavirus treatment
02 Jun 2020 //
THEGUARDIAN
BeiGene`s new BTK drug Brukinsa falls short in early launch
13 May 2020 //
FIERCE PHARMA
AstraZeneca begins clinical trial of blood cancer drug Calquence for Covid-19
19 Apr 2020 //
CAMBRIDGEINDIPENDENT
AstraZeneca to test impact of cancer drug Calquence on coronavirus patients
15 Apr 2020 //
REUTERS
AstraZeneca’s Calquence Shows Early Promise For COVID-19 Patients
13 Apr 2020 //
FORBES
EMA begins review of Kite’s CAR-T for mantle cell lymphoma
30 Jan 2020 //
PMLIVE
Docs are excited about CAR-T, BTK drugs, survey finds.
08 Jan 2020 //
FIERCE PHARMA
Docs are excited about CAR-T, BTK drugs, survey finds.
07 Jan 2020 //
FIERCE PHARMA
Docs are excited about CAR-T, BTK drugs, survey finds.
07 Jan 2020 //
FIERCE PHARMA
AZ’ Calquence boosts PFS in CLL patients
09 Dec 2019 //
PHARMATIMES
CALQUENCE Approved in the US for Adult With Chronic Lymphocytic Leukemia
22 Nov 2019 //
BUSINESS WIRE
AstraZeneca`s Calquence steps up to challenge Imbruvica
21 Nov 2019 //
FIERCE PHARMA
CALQUENCE® Data To Show Improved Progression-Free Survival In PhIII
07 Nov 2019 //
BUSINESSWIRE
Is AbbVie`s Imbruvica concerned about AZ`s rising Calquence?
01 Nov 2019 //
FIERCEP HARMA
AbbVie and AstraZeneca settle respective patent suits over rival cancer drugs
24 Oct 2019 //
SEEKINGALPHA
AZ’ Calquence granted US Breakthrough Therapy Designation
14 Aug 2019 //
PHARMA TIMES
AstraZeneca Has Dazzled in Recent Cancer Trials, but Faces Stiff Competition
27 Jun 2019 //
BIOSPACE
AstraZeneca`s Calquence sets Imbruvica in its sights
17 Jun 2019 //
FIERCE PHARMA
